David Shaw’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $126M | Sell |
1,548,919
-91,462
| -6% | -$6.6M | 0.06% | 364 |
|
|
2026
Q1 | $112M | Sell |
1,640,381
-104,610
| -6% | -$7.41M | 0.07% | 336 |
|
|
2025
Q4 | $133M | Sell |
1,744,991
-429,617
| -20% | -$31.2M | 0.07% | 318 |
|
|
2025
Q3 | $133M | Sell |
2,174,608
-263,089
| -11% | -$13.7M | 0.08% | 313 |
|
|
2025
Q2 | $119M | Buy |
2,437,697
+992,418
| +69% | +$47.1M | 0.08% | 293 |
|
|
2025
Q1 | $73.7M | Sell |
1,445,279
-97,013
| -6% | -$4.84M | 0.07% | 353 |
|
|
2024
Q4 | $69.6M | Buy |
1,542,292
+122,753
| +9% | +$5.25M | 0.05% | 446 |
|
|
2024
Q3 | $52.7M | Buy |
1,419,539
+61,901
| +5% | +$2.07M | 0.05% | 489 |
|
|
2024
Q2 | $41.5M | Buy |
1,357,638
+131,890
| +11% | +$4.27M | 0.04% | 514 |
|
|
2024
Q1 | $35.7M | Sell |
1,225,748
-121,219
| -9% | -$3.4M | 0.03% | 616 |
|
|
2023
Q4 | $37.1M | Buy |
1,346,967
+506,158
| +60% | +$11.6M | 0.03% | 595 |
|
|
2023
Q3 | $18.8M | Buy |
840,809
+107,821
| +15% | +$4.01M | 0.02% | 895 |
|
|
2023
Q2 | $29.8M | Buy |
732,988
+27,470
| +4% | +$1.34M | 0.03% | 651 |
|
|
2023
Q1 | $34.2M | Sell |
705,518
-239,361
| -25% | -$10.9M | 0.04% | 597 |
|
|
2022
Q4 | $36.1M | Sell |
944,879
-109,106
| -10% | -$4.54M | 0.04% | 576 |
|
|
2022
Q3 | $52.9M | Buy |
1,053,985
+101,198
| +11% | +$4.96M | 0.06% | 372 |
|
|
2022
Q2 | $38.2M | Sell |
952,787
-84,603
| -8% | -$2.97M | 0.04% | 516 |
|
|
2022
Q1 | $38.7M | Sell |
1,037,390
-157,590
| -13% | -$6.07M | 0.04% | 613 |
|
|
2021
Q4 | $47.6M | Sell |
1,194,980
-4,553
| -0.4% | -$174K | 0.04% | 572 |
|
|
2021
Q3 | $44.6M | Sell |
1,199,533
-10,526
| -0.9% | -$432K | 0.04% | 583 |
|
|
2021
Q2 | $51.1M | Buy |
1,210,059
+41,004
| +4% | +$1.76M | 0.04% | 530 |
|
|
2021
Q1 | $55.4M | Buy |
1,169,055
+195,412
| +20% | +$11.6M | 0.05% | 443 |
|
|
2020
Q4 | $59.4M | Buy |
973,643
+94,172
| +11% | +$5.55M | 0.05% | 430 |
|
|
2020
Q3 | $41.1M | Sell |
879,471
-15,096
| -2% | -$743K | 0.04% | 496 |
|
|
2020
Q2 | $45.4M | Sell |
894,567
-101,403
| -10% | -$4.98M | 0.05% | 385 |
|
|
2020
Q1 | $44.4M | Sell |
995,970
-64,616
| -6% | -$3.25M | 0.07% | 317 |
|
|
2019
Q4 | $50.9M | Buy |
1,060,586
+248,942
| +31% | +$10.6M | 0.06% | 381 |
|
|
2019
Q3 | $27.4M | Sell |
811,644
-25,578
| -3% | -$1.11M | 0.03% | 627 |
|
|
2019
Q2 | $37.7M | Sell |
837,222
-45,414
| -5% | -$1.79M | 0.05% | 469 |
|
|
2019
Q1 | $33.2M | Sell |
882,636
-113,434
| -11% | -$3.81M | 0.04% | 508 |
|
|
2018
Q4 | $34.2M | Sell |
996,070
-760,819
| -43% | -$27.4M | 0.05% | 471 |
|
|
2018
Q3 | $82.6M | Sell |
1,756,889
-630,431
| -26% | -$26.1M | 0.1% | 254 |
|
|
2018
Q2 | $80.5M | Buy |
2,387,320
+53,717
| +2% | +$1.68M | 0.11% | 230 |
|
|
2018
Q1 | $63.1M | Sell |
2,333,603
-274,829
| -11% | -$6.96M | 0.09% | 279 |
|
|
2017
Q4 | $43.5M | Buy |
2,608,432
+245,464
| +10% | +$4.15M | 0.06% | 394 |
|
|
2017
Q3 | $47.3M | Sell |
2,362,968
-358,707
| -13% | -$7.02M | 0.07% | 335 |
|
|
2017
Q2 | $49.9M | Buy |
2,721,675
+744,599
| +38% | +$10M | 0.08% | 288 |
|
|
2017
Q1 | $19.5M | Buy |
1,977,076
+474,164
| +32% | +$5.74M | 0.03% | 587 |
|
|
2016
Q4 | $16.4M | Buy |
1,502,912
+751,735
| +100% | +$7.89M | 0.03% | 707 |
|
|
2016
Q3 | $10.5M | Buy |
751,177
+722,416
| +2,512% | +$5.87M | 0.02% | 857 |
|
|
2016
Q2 | $202K | Buy |
+28,761
| New | +$211K | ﹤0.01% | 3182 |
|
|
2016
Q1 | – | Sell |
-16,492
| Closed | -$534K | – | 3708 |
|
|
2015
Q4 | $534K | Sell |
16,492
-37,593
| -70% | -$1.11M | ﹤0.01% | 3052 |
|
|
2015
Q3 | $1.44M | Buy |
+54,085
| New | +$2.31M | ﹤0.01% | 2334 |
|
|
2015
Q1 | – | Sell |
-4,885
| Closed | -$253K | – | 3927 |
|
|
2014
Q4 | $253K | Buy |
+4,885
| New | +$215K | ﹤0.01% | 3715 |
|
|
2014
Q3 | – | Sell |
-24,292
| Closed | -$635K | – | 4335 |
|
|
2014
Q2 | $635K | Buy |
+24,292
| New | +$520K | ﹤0.01% | 3323 |
|
Other funds holding PTCT
RI
JT
David Shaw's PTCT Position: Q2 2026 in Review
David Shaw reduced its PTC Therapeutics (PTCT) stake by 5.6% in Q2 2026, selling an estimated $6.6M and leaving 1,548,919 shares worth $126M. The position accounts for 0.06% of the portfolio, ranked #364.
David Shaw first reported a position in PTCT in Q2 2014 and has held it in 45 quarters since. The position peaked at $133M in Q3 2025. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- David Shaw held 1,548,919 shares of PTC Therapeutics worth $126M as of Q2 2026.
- David Shaw sold 91,462 PTC Therapeutics shares in Q2 2026, an estimated $6.6M.
- PTC Therapeutics made up 0.06% of David Shaw's portfolio in Q2 2026, its #364 holding.
- David Shaw first reported a position in PTC Therapeutics in Q2 2014 and has held it in 45 quarters since.
- David Shaw's PTC Therapeutics position peaked at $133M in Q3 2025.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.